TUCSON, Ariz., June 22, 2022 — Critical Path Institute (C-Path) is pleased to announce it has received the DIA 2022 Americas Inspire Award for Outstanding Contribution to Health. This prestigious honor is conferred upon an individual, group or organization that has made significant and innovative contributions to advancing global health.Continue reading
Author Archives: Roxan Olivas
C-Path Launches Unique Translational Therapeutics Accelerator with Support from Cottrell Foundation
The global accelerator will transform academic discoveries to drug development opportunitiesContinue reading
Longtime Pharmaceutical Executive to Lead C-Path’s Sickle Cell Disease Consortium
TUCSON, Ariz., April 14, 2022 – Critical Path Institute (C-Path) has named Sergey Rakhilin, Ph.D., as Executive Director of its Critical Path for Sickle Cell Disease (CP-SCD) Consortium.Continue reading
C-Path European Nonprofit Established in Amsterdam
C-Path European Nonprofit Established in Amsterdam
C-Path in Europe works seamlessly with its U.S. counterpart to advance the development of novel regulatory-endorsed methodologies to accelerate medical product developmentContinue reading
C-Path and Tufts Medical Center Collaborate on EHR Data Transfer
The endeavor represents a major milestone for C-PathContinue reading
C-Path Board Member Dr. Robert Califf Confirmed as New FDA Commissioner
Statement from Critical Path Institute Board Chair Wainwright Fishburn on the Senate Confirmation of Dr. Robert M. Califf, MD, MACC, as Commissioner of the U.S. Food and Drug Administration (FDA), Feb. 15, 2022.Continue reading
C-Path and the European Joint Programme on Rare Diseases to Expand Global Impact and Partnership
PARIS, France and TUCSON, Ariz., U.S., February 1, 2022 — Critical Path Institute (C-Path), an independent global nonprofit organization, and the European Joint Programme on Rare Diseases (EJP RD), an initiative that has received funding from the European Union’s Horizon 2020 research and innovation programme, have announced a collaboration to advance technologies and methodologies that are fit for regulatory purposes to further global rare disease research and drug development.Continue reading
C-Path Appoints Health Outcomes Expert as Executive Director of the Rare Disease COA Consortium
Dr. Lindsey Murray will lead C-Path’s New Rare Disease COA ConsortiumContinue reading
C-Path Launches Rare Disease Clinical Outcome Assessment Consortium
The Rare Disease COA Consortium aims to advance patient-focused assessment of clinical benefit in treatment trials for rare diseasesContinue reading
C-Path’s ePRO Consortium Announces Rebranding, Changes Name to eCOA Consortium
TUCSON, Ariz., January 11, 2022 — Critical Path Institute (C-Path) is pleased to announce the Electronic Patient-Reported Outcome (ePRO) Consortium is now the Electronic Clinical Outcome Assessment (eCOA) Consortium. This rebranding more accurately reflects the expanded portfolio range of work performed by the consortium, the actual capabilities of member firms and the scope and significance of the consortium’s role. The new name was chosen to more authentically characterize the mission and aims of the consortium, which have evolved significantly since its inception in 2011.Continue reading